VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32337664/

⇱ Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that ⁓ 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and "Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)" in China, so as to provide reference for the treatment of COVID-19.

PubMed Disclaimer

Conflict of interest statement

Shengyu Zhang, Lei Li, Aizong Shen, Yongwu Chen and Zhigang Qi declare that they have no conflict of interest.

Figures

👁 Fig. 1
Fig. 1
The potential mechanism of tocilizumab in the treatment of cytokine storm induced by COVID-19 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2; IL interleukin, MAPK mitogen-activated protein kinase

Comment in

  • Tocilizumab, Adipokines and Severe Complications of COVID-19.
    Fioravanti A, Porcelli B, Terzuoli L, Bacarelli MR, Tenti S, Cheleschi S. Fioravanti A, et al. Clin Drug Investig. 2020 Sep;40(9):891-892. doi: 10.1007/s40261-020-00950-2. Clin Drug Investig. 2020. PMID: 32661912 Free PMC article. No abstract available.

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2019;2020:2020. doi: 10.1101/2020.02.06.20020974. - DOI
    1. Xu KJ,Cai HL,Shen YH,et a1. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao (Yi Xue Ban). 2020. https://kns.cnki.net/kcms/detail/33.1248.R.20200222.1417.002.html. Accessed 3 Mar 2020 (in Chinese).
    1. General Office of the National Health Committee of China, China Traditional Chinese Medicine Administration Office. Diagnosis and treatment plan of novel coronavirus pneumonia (seventh trial edition). 2020. http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af.... Accessed 11 Mar 2020.
    1. Jennifer RT, Marcus JK, Cameron PS, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. - PMC - PubMed
    1. Fei ZY, Dong H, Qian QJ, et al. Analysis of pathogens and risk factors for death in elderly patients with severe pneumonia. Zhong Hua Yi Yuan Gan Ran Xue Za Zhi. 2019;29(3):380–383.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
👁 Springer full text link
Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.